Tumor Growth Rate (TGR) Predicts Clinical Outcomes for Advanced Non-small Cell Lung Cancer Undergoing Immunotherapy.

Sun Yat-sen University350 enrolled

Overview

We hypothesized that TGR could serve as an early predictor of outcomes for aNSCLC patients undergoing immune checkpoint inhibitors (ICIs). A retrospective analysis was conducted to investigate the association of TGR with response and long-term survival of aNSCLC patients undergoing ICI therapy.

Tumor growth rate (TGR) signifies percentage change in tumor size per month (%/m). Electronic medical records were retrospectively reviewed for all histologically confirmed aNSCLC patients undergoing anti-PD-1/PD-L1 therapy at Sun Yat-Sen University Cancer Center (SYSUCC) between August 2016 and June 2018. All response and outcome evaluation were determined as per RECIST 1.1 by two senior radiologists blinded to patients'information. Discrepancy was solved by consensus. X-tile software was used to determine cut-off values that maximumly differentiate overall survival (OS). Log-rank tests and Cox regression models were performed for survival analysis. The predictive value of TGR for clinical outcomes in ICI-treated aNSCLC patients was validated in two external cohorts, recruited form Guangdong Province Traditional Chinese Medical Hospital and Shanghai Chest Hospital.

Study Type

OBSERVATIONAL

Enrollment

350

Conditions

Non-Small Cell Lung Cancer

Interventions

This item is not applicable to our observational study.OTHER

This item is not applicable to our observational study.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically confirmed aNSCLC patients * Having received anti-PD-1/PD-L1 therapy * Must have two consecutive computed tomography (CT) scans upon early treatment (from baseline to the first imaging evaluation) Exclusion Criteria: * Lacking available computed tomography (CT) evaluation at any of two time points-baseline and the first evaluation * Without measurable lesions at baseline CT scan * Having received local anticancer therapy during ICI treatment, for example, radiotherapy and radiofrequency ablation

Locations (3)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

RECRUITING

Guangdong Provincial Hospital of Traditional Chinese Medicine

Guangzhou, Guangdong, China

RECRUITING

Shaihai Chest Hospital

Shanghai, Shanghai Municipality, China

RECRUITING

Outcomes

Primary Outcomes

Overall survival of patients undergoing ICI monotherapy

Overall survival (OS) was defined as the time from immunotherapy initiation to death from any causes.

Time frame: From date of ICI treatment initiation until the date of death from any causes, assessed up to 100 months.

Secondary Outcomes

Progression-free survival of patients undergoing ICI monotherapy.

Progression-free survival was calculated from ICI initiation to radiologically-defined progression or death from any causes.

Time frame: From date of ICI treatment initiation until the date of first documented progression or date of death from any causes, whichever came first, assessed up to 100 months.

Central Contacts

Shaodong Hong, MD

CONTACT

+8615920527656 hongshd@sysucc.org.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.